Head to Head Review: Alliqua BioMedical (ALQA) vs. Its Peers
Alliqua BioMedical (NASDAQ: ALQA) is one of 88 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its competitors? We will compare Alliqua BioMedical to related companies based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Volatility & Risk
Alliqua BioMedical has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Alliqua BioMedical’s competitors have a beta of 1.04, suggesting that their average stock price is 4% more volatile than the S&P 500.
This is a breakdown of recent recommendations for Alliqua BioMedical and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alliqua BioMedical Competitors||199||1215||2569||89||2.63|
Alliqua BioMedical currently has a consensus price target of $14.17, indicating a potential upside of 601.32%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 5.07%. Given Alliqua BioMedical’s stronger consensus rating and higher probable upside, equities analysts clearly believe Alliqua BioMedical is more favorable than its competitors.
This table compares Alliqua BioMedical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alliqua BioMedical Competitors||-130.41%||-39.55%||-10.33%|
Earnings and Valuation
This table compares Alliqua BioMedical and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Alliqua BioMedical||$18.24 million||-$28.24 million||-0.20|
|Alliqua BioMedical Competitors||$1.05 billion||$131.13 million||173.13|
Alliqua BioMedical’s competitors have higher revenue and earnings than Alliqua BioMedical. Alliqua BioMedical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
66.6% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 15.8% of Alliqua BioMedical shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Alliqua BioMedical competitors beat Alliqua BioMedical on 8 of the 12 factors compared.
About Alliqua BioMedical
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers SilverSeal.
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.